Forward looking statements

Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based on management’s current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company’s annual report on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company’s projections or forward-looking statements. All third-party marks—® and ™—are the property of their respective owners.

NON-GAAP FINANCIAL MEASURES

In this presentation, the Company’s financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. Management believes that presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the Company’s core operating results and comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the Company’s business. A reconciliation of the GAAP to non-GAAP financial results is provided under the investor section of Myriad’s corporate website at www.myriad.com.
Who we are, what we do, and why it matters

Illuminating the path to better health through genetic insights.

Our purpose-led Mission

We advance health and wellbeing for all, empowering every individual by revealing the answers inside each of us.

Our Vision

As a leader in genetic testing and precision medicine, we provide insights that help people take control of their health, and enable healthcare providers to better detect, treat and prevent disease.

Health. Illuminated.
Empowering patients with answers and insights for better health

2022 Annual letter to stakeholders

At Myriad Genetics, our mission is to advance health and well-being for all, empowering patients to take control of their health and enabling healthcare providers to better detect, treat and prevent disease.

For more than 30 years, we’ve partnered with healthcare providers to advance genetic testing and precision medicine. Now, we are taking the same kind of scientific discipline and rigor that goes into our products and applying it to the management of our business.

In 2021, we executed on our transformation and growth plan, laying a strong foundation for long-term sustainable growth, profitability, and innovation.”

Paul J. Diaz
President and CEO
Myriad Genetics

7 million+
geneic tests performed

60,000+
active ordering physicians

95%
of payers cover certain Myriad testing in network

1,000+
scientific publications to date

86,000+
eligible patients assisted with financial aid under Myriad uninsured and underinsured programs in 2021 – total value exceeding $49 million

2,300
employees worldwide – 800 sales, medical, and customer service team members

©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com 5 May 2022
First quarter operating and financial highlights

1. Total revenue of $164.9 million increased 11% YoY after excluding the impact of the divested Vectra, Myriad RBM and myPath businesses.

2. Diagnostic test volumes of 241,000 increased 10% YoY after excluding divested businesses. ASP in the quarter increased 1% YoY, stable ASP for 7 quarters in a row.

3. GAAP total operating expenses were $142.5 million; decreasing $27.0 million YoY. Adjusted operating expenses decreased $7.0 million YoY to $120.0 million.

4. GAAP operating loss in the quarter was $25.6 million; improving $21.1 million YoY. Adjusted operating loss was $2.8 million, improving $0.5 million YoY.

5. Diluted GAAP EPS of $(0.26) improved $0.26 YoY and adjusted EPS of $(0.03) improved $0.03 YoY. In 2022, we remain on track to return to profitability.

Ended the quarter with $339.2 million in cash, cash equivalents and investments and no debt outstanding.
Strategic priorities

A trusted, differentiated partner with specialized expertise

Innovation that improves clinical outcomes, ease of use, and access
Developing and enhancing best-in-class products to support growth, improve patient and provider experience and reach more patients of all backgrounds

Enterprise capabilities to accelerate growth and scale to market opportunity
Investing in tech-enabled commercial tools to drive engagement, improve revenue cycle management, and reduce complexity & cost

Focus on execution and delivery of consistent results
Committed to disciplined management of a key set of initiatives to fulfill our mission and drive long-term growth and profitability
Expanded Precise Tumor partnership with Intermountain Precision Genomics to accelerate launch of liquid biopsy therapy selection (LBTS) test offering

- Sales & marketing of LBTS
- Expands Precise™ Oncology Solutions
- Sample collection & accessioning
- Combines & delivers clinical report
- Billing & collections

Sample

- Validates LBTS test (Illumina TSO500 ctDNA assay)
- Laboratory performs TSO500 ctDNA test
- Reports clinical results to Myriad

Results
In-house Measurable Residual Disease (MRD) solution built upon Myriad Genetics' existing core competencies

Current status:
• Prototype underway; pharma availability expected in ’23
• Protocols for clinical studies undergoing review

Expected performance:
• High sensitivity, high specificity, and fast turnaround time
• Actionable information about nature of recurrent cancer

MRD Workflow with current Myriad capabilities

Pre-operative tumor assessment
1. Tumor + normal sample prep and sequencing
2. Bioinformatic identification of somatic variants

MyChoice®

Post-operative residual-disease monitoring
3. cfDNA isolation; targeted NGS with AMPLIFY™
4. Detect presence or absence of tumor cfDNA

Prequel® & FirstGene®
Mental Health

Using genetic insights to help physicians understand how genetic alterations impact patient response to antidepressants and other drugs.

Operating Results

Q1 '22 volume: 
~84k
Q1 '22 revenue: 
$29.3M

Quarterly highlights

- GeneSight volumes in the first quarter reach one of its highest levels ever
- GeneSight Psychotropic 4.1 launches with key updates including three new medications:
  - suvorexant (Belsomra®)
  - lemborexant (Dayvigo®)
  - viloxazine (Qelbree®)
- WedMD features GeneSight Mental Health Monitor in front-page article on the treatment of teenagers with mental illness
Leading health and wellness with best-in-class genetic insights for women of all ancestries, assessing cancer risk and offering prenatal solutions.

Operating Results

Q1 '22 volume: ~113k
Q1 '22 revenue: $65.5M

Quarterly highlights

- MyRisk with RiskScore remains the only test of its kind for women of all ancestries
- Launched new Virtual Care Solution in partnership with Genome Medical to provide end-to-end guidance for MyRisk testing
- Prenatal first quarter revenue up 35% year-over-year
- Patient education tools experience spike in demand

MyRisk
Hereditary Cancer Test

with RiskScore®
for all ancestries

Foresight®
Carrier Screen

Prequel®
Prenatal Screen

FirstGene®
Comprehensive Prenatal Screen

2023E Launch

©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com
5 May 2022
Clarifying cancer treatment with genetic insights and companion diagnostic tests that are designed to work with corresponding drugs and treatments.

Quarterly highlights
- Successful March 2022 launch of Precise Tumor for molecular tumor profiling
- New partnership with Intermountain Precision Genomics to launch Precise Liquid
- BRACAnalysis CDx receives FDA approval for use with Lynparza® in early-stage breast cancer treatment
- Prolaris prostate cancer prognostic test sets record volume levels in March 2022

Operating Results
- Q1 ‘22 volume: ~44k
- Q1 ‘22 revenue: $69.8M
Bryan Riggsbee, Chief Financial Officer
Myriad continues to stabilize business and improve operating and financial results

Financial highlights

- Maintained both GAAP & adjusted gross margins within guidance
- Stable ASP results for 7 consecutive quarters showing benefits of improved revenue cycle management
- Improved GAAP loss per share by $0.26 and adjusted loss per share by $0.03 compared to the first quarter of last year
- ~$340M in cash, cash equivalents and investments with no debt

Q1’22 YoY volume*:
+10%

Q1’22 YoY revenue*:
+11%

*excludes divested assets
## Consolidated quarterly highlights

### Revenue excluding divested assets, adjusted gross margin, adjusted operating income, adjusted EPS

<table>
<thead>
<tr>
<th><em>In millions</em></th>
<th>March 2022</th>
<th>December 2021</th>
<th>March 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue</strong>*</td>
<td>$164.6</td>
<td>$160.8</td>
<td>$148.4</td>
</tr>
<tr>
<td>Annual change</td>
<td>11%</td>
<td>19%</td>
<td>—</td>
</tr>
<tr>
<td><strong>Adjusted gross margin</strong></td>
<td>71.1%</td>
<td>71.8%</td>
<td>71.5%</td>
</tr>
<tr>
<td>Annual change</td>
<td>(40 bp)</td>
<td>170 bp</td>
<td>—</td>
</tr>
<tr>
<td><strong>Adjusted op income (loss)</strong></td>
<td>($2.8)</td>
<td>$0.1</td>
<td>($3.3)</td>
</tr>
<tr>
<td>Annual change</td>
<td>$0.5</td>
<td>$11.4</td>
<td>—</td>
</tr>
<tr>
<td><strong>Adjusted earnings per share</strong></td>
<td>($0.03)</td>
<td>($0.02)</td>
<td>($0.06)</td>
</tr>
<tr>
<td>Annual change</td>
<td>$0.03</td>
<td>$0.10</td>
<td>—</td>
</tr>
<tr>
<td><strong>Revenue from prior period collections</strong>*</td>
<td>$12</td>
<td>$7</td>
<td>$9</td>
</tr>
</tbody>
</table>
## First quarter 2022 — revenue by product, excluding divested assets

<table>
<thead>
<tr>
<th>In millions</th>
<th>2022</th>
<th>2021</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Women’s Health</td>
<td>Oncology</td>
<td>Mental Health</td>
</tr>
<tr>
<td>Hereditary cancer</td>
<td>$33.6</td>
<td>$37.3</td>
<td>—</td>
</tr>
<tr>
<td>Prenatal</td>
<td>31.9</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Pharmacogenomics</td>
<td>—</td>
<td>—</td>
<td>29.3</td>
</tr>
<tr>
<td>Tumor profiling</td>
<td>—</td>
<td>32.5</td>
<td>—</td>
</tr>
<tr>
<td>Total core business revenue</td>
<td>$65.5</td>
<td>$69.8</td>
<td>$29.3</td>
</tr>
</tbody>
</table>
## First quarter 2022 revenue and test performance

<table>
<thead>
<tr>
<th>Category</th>
<th>BRACAnalysis® CDx</th>
<th>MyRisk™</th>
<th>Year over Year %</th>
<th>Sequential %</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hereditary cancer</strong></td>
<td>(7%)</td>
<td>(12%)</td>
<td>(5%)</td>
<td>(10%)</td>
</tr>
<tr>
<td><strong>Prenatal</strong></td>
<td><strong>Foresight</strong></td>
<td>(1%)</td>
<td>6%</td>
<td>3%</td>
</tr>
<tr>
<td><strong>Tumor profiling</strong></td>
<td>MyChoice® CDx</td>
<td>EndoPredict®</td>
<td>(12%)</td>
<td>23%</td>
</tr>
<tr>
<td><strong>Pharmacogenomics</strong></td>
<td>GeneSight®</td>
<td>(5%)</td>
<td>3%</td>
<td>2%</td>
</tr>
<tr>
<td><strong>Overall company</strong></td>
<td>(5%)</td>
<td>(3%)</td>
<td>3%</td>
<td>2%</td>
</tr>
<tr>
<td><strong>Overall company (excluding divestitures)</strong></td>
<td>11%</td>
<td>10%</td>
<td>2%</td>
<td>2%</td>
</tr>
</tbody>
</table>

ASP in the first quarter increased 1% YoY* and 1% sequentially*.  
*After excluding divested businesses*
Myriad strengths and strategic advantages

Leader in genetic testing and precision medicine

- Successfully implementing transformation and growth strategy
- Broad and growing commercial capabilities with 60K healthcare providers ordering Myriad products across Women’s Health, Oncology and Mental Health
- Commercial platform with market-leading breadth of payer relationships and revenue cycle management capabilities
- Trusted, differentiated healthcare partner with specialized expertise
Thank you